<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567955</url>
  </required_header>
  <id_info>
    <org_study_id>HPV 2355</org_study_id>
    <nct_id>NCT02567955</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Gardasil-9 and Cervarix</brief_title>
  <official_title>Immunogenicity and Safety of Gardasil-9 and Cervarix When Administered to 9-10-year-old Subjects According to 0-6 Month Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A ninevalent HPV vaccine (Gardasil-9) has been recently approved for clinical use. No data on
      immunogenicity and safety of interchangeable use of the ninevalent and the bivalent vaccine
      (Cervarix) are available. The main objective of this study is to assess the immunogenicity of
      ninevalent and bivalent HPV vaccines when administered to 9-10-year-old girls and boys
      according to 0-6 month schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proportion of subjects with detectable antibodies and antibody geometrical mean titers to
      9 HPV genotypes included in the Gardasil-9 vaccine will be assessed 1 and 6 months post-first
      dose and 1, 18 and 36 months post-second dose of vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of proportion of subjects with detectable antibodies to 9 HPV genotypes included in the Gardasil-9 vaccine observed in two study arms</measure>
    <time_frame>36 months post-second dose of vaccine</time_frame>
    <description>A Luminex Total IgG assay will be used to assess the presence of antibodies and antibody titers to 9 HPV genotypes included in the Gardasil-9 vaccine. Luminex Units will be used for the antibody titers assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of tolerability profile of Gardasil-9 and Cervarix</measure>
    <time_frame>During 5 days after each vaccine dose administration.</time_frame>
    <description>Local and general symptoms observed after each vaccine dose will be assessed by using a standardized diary card. Proportion of subjects who reported local and/or general symptoms will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>HPV Vaccines Immunogenicity and Safety</condition>
  <arm_group>
    <arm_group_label>Immunogenicity two doses of Gardasil-9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive two doses of Gardasil-9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunogenicity Cervarix and Gardasil-9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a dose Cervarix and a dose Gardasil-9</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunogenicity two doses of Gardasil-9</intervention_name>
    <description>Subjects will receive two standard doses of Gardasil-9 (0.5 ml)</description>
    <arm_group_label>Immunogenicity two doses of Gardasil-9</arm_group_label>
    <other_name>HPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunogenicity Cervarix and Gardasil-9</intervention_name>
    <description>Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)</description>
    <arm_group_label>Immunogenicity Cervarix and Gardasil-9</arm_group_label>
    <other_name>HPV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  9-10-year-old girls and boys

        Exclusion Criteria:

          -  previously received an HPV vaccine

          -  immunosuppressed

          -  known allergy to a vaccine component
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ã‰quipe de recherche en vaccination</name>
      <address>
        <city>Quebec</city>
        <zip>G1E7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV vaccines, interchangeable use</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

